Diagnostic performance of multiplex lateral flow tests in ambulatory patients with acute respiratory illness.
Diagn Microbiol Infect Dis
; 110(1): 116421, 2024 Jul 04.
Article
in En
| MEDLINE
| ID: mdl-38972132
ABSTRACT
We assessed the performance of three different multiplex lateral flow assays manufactured by SureScreen, Microprofit and Goldsite which provide results for influenza, respiratory syncytial virus (RSV) and SARS-CoV-2. Between 4 April and 20 October 2023, 1646 patients 6 months and older presenting to an outpatient department of a hospital in Hong Kong with ≥2 symptoms or signs of an acute respiratory illness were enrolled. The point estimates for all three multiplex tests had sensitivity >80% for influenza A and SARS-CoV-2 compared to PCR, and the tests manufactured by Microprofit and Goldsite had sensitivity >84% to detect RSV. Specificity was >97% for all three tests except for the SureScreen test which had specificity 86.2% (95% CI 83.9% to 88.3%) for influenza A. Sensitivity was lower than reported by the manufacturers, resulting in a higher risk of false negatives. The three multiplex tests performed better in patients with high viral loads.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
Diagn Microbiol Infect Dis
Year:
2024
Type:
Article
Affiliation country:
China